The Enterprise Value as of December 2024 (TTM) for Akari Therapeutics, Plc (AKTX) is 10.29M

According to Akari Therapeutics, Plc’s latest financial reports and current stock price. The company's current Enterprise Value is 10.29M. This represents a change of -50.82% compared to the average of 20.93M of the last 4 quarters.

Akari Therapeutics, Plc (AKTX) Historical Enterprise Value (quarterly & annually)

How has AKTX Enterprise Value performed in the past?

The mean historical Enterprise Value of Akari Therapeutics, Plc over the last ten years is 655.16M. The current 10.29M Enterprise Value has changed 57.08% with respect to the historical average. Over the past ten years (40 quarters), AKTX's Enterprise Value was at its highest in in the September 2021 quarter at 1.50B. The Enterprise Value was at its lowest in in the March 2018 quarter at 4.29M.

Akari Therapeutics, Plc (AKTX) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Akari Therapeutics, Plc Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Akari Therapeutics, Plc (AKTX) Average Enterprise Value

How has AKTX Enterprise Value performed in the past?

The current Enterprise Value of Akari Therapeutics, Plc (AKTX) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Akari Therapeutics, Plc (AKTX) Enterprise Value vs. Peers

How is AKTX’s Enterprise Value compared to its peers?

Akari Therapeutics, Plc’s Enterprise Value is less than Armata Pharmaceuticals, Inc. (193.38M), less than Anebulo Pharmaceuticals, Inc. (31.01M), greater than Scopus BioPharma Inc. (-111950.00), greater than Processa Pharmaceuticals, Inc. (-59538.00), less than Salarius Pharmaceuticals, Inc. (0), greater than Axcella Health Inc. (-692559.00), greater than Magenta Therapeutics, Inc. (-14986000.00), greater than Histogen Inc. (-114170976.00), greater than Pulmatrix, Inc. (-4487565.00), greater than Capricor Therapeutics, Inc. (10.26M), less than Diffusion Pharmaceuticals Inc. (575.76M), less than Soleno Therapeutics, Inc. (10.50M), less than Oncorus, Inc. (1.89B), less than Sonnet BioTherapeutics Holdings, Inc. (42.71M), greater than Landos Biopharma, Inc. (4.31M), less than null (42.62M),

Build a custom stock screener for Akari Therapeutics, Plc (AKTX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Akari Therapeutics, Plc using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Akari Therapeutics, Plc (AKTX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Akari Therapeutics, Plc or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.